Add
MAXY to Portfolio
Set Alert
Email to a
Friend
| |||
|
|
Quotes & Info
|
| MAXY > SEC Filings for MAXY > Form 8-K on 11-May-2009 | All Recent SEC Filings |
11-May-2009
Results of Operations and Financial Condition, Other Events, Financial Statements and
On May 11, 2009, Maxygen, Inc. (the "Company") issued a press release announcing its financial results for the three months ended March 31, 2009. A copy of the press release announcing these financial results and certain other information is attached as Exhibit 99.1 to this report.
On May 7, 2009, the Company issued a press release announcing that it has entered into an agreement with Cangene Corporation under which it has granted Cangene an option to obtain an exclusive license to Maxygen's proprietary MAXY-G34 protein therapeutic for use in treating acute radiation syndrome (ARS). A copy of the press release is attached as Exhibit 99.2 to this report.
(d) Exhibits
99.1 Press Release dated May 11, 2009, entitled "Maxygen Reports First Quarter
2009 Financial Results."
99.2 Press Release dated May 7, 2009, entitled "Maxygen Announces MAXY-G34
Licensing Arrangement with Cangene for Acute Radiation Syndrome."
|
|
|